iQure Pharma
$4.9Mtotal raised · 5 rounds on record
$650klatest round · Venture round · May 2026 · 5 mo ago
1backers · i&i Bio
10+team · employees, estimated range
Overview
IQure restores glutamate homeostasis by targeting astrocyte biology, breaking the cycle of excitotoxicity across CNS diseases.
Funding and backers
Total raised
$4.9M
5 rounds on record
Latest round
$650k
Venture round · May 2026 · 5 mo ago
Team
11-50
employees, estimated range
Backers
1
i&i Bio
The money's age
Fresh money
5 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 27
Raised a round Venture round $650k · SEC Form D
Sep 9, 2025
Raised a round Venture round $2.8M · SEC Form D
Dec 20, 2024
Took on debt financing $1.4M · SEC Form D
Apr 5, 2024
Took on debt financing $220k · SEC Form D
Oct 4, 2023
Raised a round Venture round $1.5M · SEC Form D
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | May 2026 | $650k | — | SEC Form D |
| Venture round | Sep 2025 | $2.8M | — | SEC Form D |
| Debt Financing | Dec 2024 | $1.4M | — | SEC Form D |
| Debt Financing | Apr 2024 | $220k | — | SEC Form D |
| Venture round | Oct 2023 | $1.5M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | iQure Pharma Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Pawel ZolnierczykExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
We believe that modeling biology is becoming solvable. Theorema builds Causal Disease Models.
Biologics Beyond Boundaries. Developing first-in-class therapeutics to treat brain cancers and CNS diseases.
We will discover the next generation of precision medicines by targeting the molecular machines that underlie human disease.
Advancing medicines to restore homeostasis. Cajal Therapeutics is developing novel medicines for serious diseases, including anemias of…
Hyku Biosciences is developing the next generation of small molecule medicines by targeting histidine, tyrosine and lysine binding pockets…
A game that helps you manage money, stop impulse buys, and break the cycle of shame. Get dopamine hits for saving, not spending.
Financials
Total raised
$6.6M
Latest round
Venture - Series Unknown
Funding rounds
5
People
Pawel Zolnierczyk
Executive Officer
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
i&i BioVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Princeton
United States
HQ
iQure Pharma Inc.
10-50 est. staff
475 Wall Street, Princeton, NJ 08540, USA